VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds Buys 181,818 Shares

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds purchased 181,818 shares of the company’s stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the purchase, the chief executive officer now directly owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. The trade was a 8.59 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.53 on Friday. The stock has a fifty day simple moving average of $0.59 and a two-hundred day simple moving average of $0.64. VolitionRx Limited has a 52-week low of $0.43 and a 52-week high of $1.02. The firm has a market capitalization of $48.93 million, a PE ratio of -1.47 and a beta of 1.09.

Wall Street Analysts Forecast Growth

VNRX has been the topic of several analyst reports. D. Boral Capital reiterated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Thursday, March 20th. StockNews.com assumed coverage on VolitionRx in a research report on Friday. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC purchased a new position in shares of VolitionRx in the fourth quarter worth $29,000. Millennium Management LLC purchased a new position in shares of VolitionRx during the fourth quarter valued at about $36,000. Northern Trust Corp increased its holdings in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. boosted its stake in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.